Xerostomia can have a major impact on the quality of life of the PCa patients that receive the potentially life-elongating PSMA-TRT: in a recent study, 10% of the patients chose to discontinue their treatment for this reason [84]. Here, FOLH1 is linked to posterior cortical atrophy.